[go: up one dir, main page]

AR056867A1 - Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas. - Google Patents

Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.

Info

Publication number
AR056867A1
AR056867A1 ARP060102745A ARP060102745A AR056867A1 AR 056867 A1 AR056867 A1 AR 056867A1 AR P060102745 A ARP060102745 A AR P060102745A AR P060102745 A ARP060102745 A AR P060102745A AR 056867 A1 AR056867 A1 AR 056867A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
crfrf
carbon atoms
aryl
Prior art date
Application number
ARP060102745A
Other languages
English (en)
Inventor
Jennifer X Qiao
Tammy C Wang
James C Sutton
Timur Gungor
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR056867A1 publication Critical patent/AR056867A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Estos compuestos son inhibidores selectivos del receptor P2Y1, humano que pueden ser utilizados como medicamentos. Composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), o un estereoisomero, tautomero, sal farmacéuticamente aceptable, solvato del mismo, en donde el anillo A es arilo C6-10 sustituido con 0-5 R1, o un heterociclo de 5-10 miembros que comprende, átomos de carbono y 1-4 heteroátomos seleccionados de nitrogeno, NR11, O y S(O)p, en donde el heterociclo está sustituido con 0-5 R1; el anillo B es arilo C6-10 con 0-4 R7, o un heteroarilo de 5 a 10 miembros que comprende, átomos de carbono y 1-4 heteroátomos en el anillo seleccionado de nitrogeno, NR11, S(O)p, y oxígeno, en donde el heteroarilo está sustituido con 0-4 R7; el anillo D es sustituido con 0-5 R6a y se selecciona de las estructuras del grupo (2), en donde D1 es un carbociclo de 5 a 7 miembros o un heterociclo de 5-6 miembros que comprende, átomos de carbono y 0-3 heteroátomos en el anillo de N, NR11, O y S(O)p y 0-2 grupos carbonilo, y 0-3 dobles enlaces; W es NR18, O, S, -NHCOCH=CH-, -NHCO-, -NHCO2-, -NHCO2CH2-, -NHCON(Me)-, NHCOCH2NH-, -NHCOCH(Me)-, -NHCOCH2CH2-, - NHCOCH2CONH-, -NHCH2-, -NHCH2CH2CH2-, -NHSO2-, -NHSO2CH2-, -NHSO2CH=CH, -NHCONHNHCO-, o los restos del grupo de formulas (3); R1 es independientemente en cada aparicion =O, F, CI, Br, I, CF3, -CF2CF3, OCF3, -OCF2CF2H-, -OCF2CF3, SiMe3, (CRfRf)rORc, SRc, CN, NO2, (CRfRf)rNR12R13, -(CRfRf)rC(O)Rc, (CRfRf)rCO2Rc, (CRfRf)rC(O)NR12R13, C(O)NR14(CRfRf)rNR12R13, -(CRfRf)rOC(O)NR12R13, (CRfRf)rNR14C(O)NR12R13, (CRfRf)rNR14C(O)Rd, -(CRfRf)rNR14R(O)ORh, NR14(CRfRf)nC(O)Rd, -NR14CO(CRfRf)nORc, - (CH2)rCR13(=NORc), -(CH2)rC(NH2)(=NORc), -S(O)pNR12R13, -(CRfRf)rNR14S(O)pNR12R13, -NR14SO2CF3, NR14S(O)pRd, -S(O)2CF3, -S(O)Rd, -S(O)2Rd, -OP(O)(OEt)2, -O(CH2)2OP(O)(OEt)2, -N(alquil C1-4)3+CI-, 4,4,5,5-tetrametil-1,3,2-dioxaborolanilo, alquilo C1- 8 sustituido con 0-2 Ra, alquenilo C2-8 sustituido con 0-2 Ra, alquinilo C2-8 sustituido con 0-2 Ra, -(CRfRf)r-(carbociclo C3-13) sustituido con 0-5 Rb, o -(CRfRf)r-(heterocicIilo de 5 a 10 miembros) que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, NR11. O y S(O)p, en donde el heterociclo está sustituido con 0-5 Rb, alternativamente, dos R1s sobre dos átomos de carbono adyacentes son combinados con los átomos de carbono a los cuales están enlazados, para formar un carbociclo de 5 a 10 miembros o heterociclo que comprende: átomos de carbono de 0-3 heteroátomos seleccionados de N, NR11, O y S(O)p y 0-2 grupos carbonilo, en donde el carbociclo o el heterociclo es sustituido con 0-4 Rb; R6a es, independientemente en cada aparicion, =O, F, CI, Br, I, (CRiRi)rORc, SRc, CN, NO2, CF3, OCF3, -CF2CF3, -OCF2CF2H, -OCF2CF3, -(CRfRf)rNR12R13, -C(O)Rc, (CRfRf)rC(O)ORc, -(CRfRf)rC(O)NR12R13, -(CRfRf)rNR14C(O)Rd, -S(O)pNR12R13, -S(O)Rd, S(O)2Rd, Si(Me)3, Si(alquilo C1-4)3, haloalquilo C1-4, haloalquiloxi C1-4, alquiloxi C1-4, alquiltio C1-4-(alquil C1-4)-C(O)-, (alquil C1-4)-O-C(O)-, (alquil C1-4)-C(O)NH-, alquilo C1-8 sustituido con 0-1 Ra, alquenilo C2-8 sustituido con 0-1 Ra, alquinilo C2-8 sustituido con 0-1 Ra, -(CRfRf)r-(carbociclo C3-10) sustituido con 0-2 Re, o -(CRfRf)r-(heterociclo de 5 a 10 miembros) que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, NR11, O, y S(O)p, en donde el heterociclo está sustituido con 0-2 Re; alternativamente, en donde dos grupos R6a están enlazados al mismo átomo de carbono o a un átomo de silicio, junto con el átomo de carbono y el átomo de silicio, al cual están enlazados, forman un anillo carbocíclico o heterocíclico de 3 a 7 miembros que comprende: átomos de carbono de 0-3 heteroátomos seleccionado de N, NR11, O, Si y S(O)p, 0-1 carbonilo y 0-3 dobles enlaces del anillo, en donde el anillo carbocíclico o heterocíclico es sustituido con 0-3 Rb; alternativamente, cuando dos grupos R6a son enlazados a átomos adyacentes, junto con los átomos a los cuales éstos están enlazados, forman un anillo carbocíclico o heterocíclico de 5 a 7 miembros que comprenden: átomos de carbono de 0-2 heteroátomos seleccionados de N, NR11, O, Si y S(O)p, 0-1 carbonilo y 0-3 dobles enlaces del anillo, en donde el anillo carbocíclico o heterocíclico está sustituido con 0-3 Rb; R7 es independientemente en cada aparicion, H, =O, F, CI, Br, I, OCF3, CF3, ORc, SRc, CN, NO2, -NR12R13, C(O)Rc, C(O)ORc, C(O)NR12R13, NR14C(O)Rd, -S(O)pNR12R13, S(O)Rd, S(O)2Rd, alquilo C1-8 sustituido con 0-2 Ra, alquenilo C2-8 sustituido con 0-2 Ra, alquinilo C2-8 sustituido con 0-2 Ra, -(CRfRf)r(carbociclo C3-10) sustituido con 0- 3 Rb, o -(CRfRf)r-(heterociclo de 5 a 10 miembros) que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, NR7b, O y S(O)p, en donde el heterociclo está sustituido con 0-3 Rb; alternativamente, dos R7 sobre dos átomos de carbono adyacentes forman un anillo carbocíclico o heterocíclico de 5 a 7 miembros, que comprenden, átomos de carbono de 0-3 heteroátomos en el anillo seleccionados de O, N, NR7b, y S(O)p, en donde el anillo carbocíclico o heterocíclico es sustituido con 0- 2 R7c; R7b es hidrogeno, alquilo C1-4, -C(O)(alquilo C1-4), -C(O)fenilo, -C(O)bencilo o bencilo; R7c es, independientemente en cada aparicion, H, F, CI, Br, I, OCF3, CF3, ORc, SRc, CN, NO2, -NR12R13, C(O)ORc, -C(O)ORc, -C(O)NR12R13, NR14C(O)Rd, - S(O)pNR12R13, -S(O)Rd, S(O)2Rd, alquilo C1-4, fenilo sustituido con 0-3 Rb, o bencilo sustituido con 0-3 Rb, R11 es, independientemente en cada aparicion, hidrogeno, alcoxi C1-4, alquilo C1-6 sustituido con 1-5 fluoro, -(CRfRf)rC(O)NR12R13, alquilo C1-8 sustituido con 0-2 Ra, alquenilo C2-4 con 0-1 Ra, alquinilo C2-4 sustituido con 0-1 Ra, -C(O)-(alquilo C1-6), -C(O)(CH2)n(cicloalquilo C3-6), -C(O)(CH2)n(arilo C6-10), -C(O)(CH2)n(heteroarilo de 5 a 10 miembros), -C(O)O(alquilo C1-8), - C(O)O(CH2)n(cicloalquilo C3-6), -C(O)O(CH2)n(arilo C6-10), -C(O)O(CH2)n(heteroarilo de 5 a 10 miembros), -C(O)O(CH2)2-4alquilo C1-4), -C(O)NH(alquilo C1-8), -C(O)NH(CH2)n-(cicloalquilo C3-6), -C(O)NH(CH2)n-(arilo C6-10), -C(O)NH(CH2)n-(heteroarilo de 5 a 10 miembros), -S(O)2(alquilo C1-8), -S(O)2(CH2)n-(cicloalquilo C3-6), -S(O)2(CH2)n-(arilo C6-10), -S(O)2(CH2)n-(heteroarilo de 5 a 10 miembros), -(CRfRf)r-(carbociclo C3-10) o -(CRfRf)r-(heterociclo de 5 a 10 miembros); en donde los grupos alquilo, cicloalquilo, arilo y carbociclo están sustituidos con 0-2 Rb, y el heteroarilo y heterociclilo están sustituidos con 0-2 Rb y comprenden: átomos de carbono y 1-4 heteroátomos seleccionados de N, NR, O y S(O)p; R12 es independientemente, en cada aparicion, hidrogeno, alquilo C1-6 sustituido con 1-5 fluor, -(CRfRf)rC(O)NRfRf, alquilo C1-6, -C(O)(alquilo C1-6), -C(O)-(CH2)n(arilo C6-10), -C(O)(CH2)n(heteroarilo de 5 a 10 miembros), -C(O)O-(arilo C1-4), -C(O)OCH2(arilo C6-10), - (CH2)nC(O)OCH2(heteroarilo de 5 a 10 miembros), -(CH2)nOC(O)(alquilo C1-4), -(CH2)nOC(O)(arilo C6-10), -(CH2)nOC(O)(heteroarilo de 5 a 10 miembros), (CH2)nC(O)O(alquilo C1-4), (CH2)nC(O)O(arilo C6-10), (CH2)nC(O)O(heteroarilo de 5 a 10 miembros), (CH2)nC(O)NH(alquilo C1-6), (CH2)nC(O)NH(arilo C6-10), (CH2)nC(O)NH(heteroarilo de 5 a 10 miembros), (CH2)nOC(O)NH(alquilo C1-6), (CH2)nOC(O)NH(arilo C6-10), (CH2)nOC(O)NH(heteroarilo de 5 a 10 miembros), -S(O)2(alquilo C1-6), -S(O)2(CH2)n(arilo C6- 10), -S(O)2(CH2)n(heteroarilo de 5 a 10 miembros), -(CRfRf)n-(arilo C6-10), o -(CRfRf)n-(heteroarilo de 5 a 10 miembros), en donde el alquilo, y el arilo son sustituidos con 0-2 Rg; y el heteroarilo es sustituido con 0-2 Rg y comprenden: átomos de carbono y 1-4 heteroátomos seleccionados de N, NR11, O, y S(O)p; R13 es independientemente, en cada aparicion, hidrogeno, alquilo C1-6, o -(CH2)n-fenilo; alternativamente, R12 y R13, cuando son enlazados al mismo átomo de nitrogeno se combinan para formar un anillo heterocíclico de 5 a 10 miembros que comprenden: átomos de carbono y 1-2 heteroátomos adicionales seleccionados de N, NR11, O, y S(O)p; R14 es, independientemente en cada aparicion hidrogeno, alquilo C1-6 sustituido con 0-2 R14a, alquenilo C2-6 sustituido con 0-2 R14a, alquinilo C2-6 sustituido con 0-2 R14a, -(CH2)r-(carbociclo C3-10) sustituido con 0-3 Rg, o (CH2)r-(heterociclo de 5 a 10 miembros) que comprenden: átomos de carbono y 1-4 heteroátomos de N, NR11, O, y S(O)p, en donde el heterociclo es sustituido con 0-3 Rg; R14a es, independientemente en cada aparicion, hidrogeno, alquilo C1-4, ORf, CI, F, Br, I, =O, CF3, CN, NO2, -NR12R13, -C(O)Rf, -C(O)ORf, -C(O)NR12R13, o -S(O)pRf; R16 es independientemente, en cada aparicion hidrogeno, fluor, alquilo C1-6 sustituido con 0-2 Ra, alquenilo C2-6 sustituido con 0-2 Ra, alquinilo C2-6 sustituido con 0-2 Ra, -(CH2)r-fenilo sustituido con 0-2 Rb; R17 es independientemente, en cada aparicion, hidrogeno, OH, alquilo C1- 6, o -(CH2)n-fenilo; alternativamente, R16 y R17, sobre el mismo átomo de carbono que combina para formar un anillo carbocíclico o heterocíclico de 3 a 7 miembros que comprende, átomos de carbono y 0-2 heteroátomos seleccionados de N, NR11, O, y S(O)p, 0-1 carbonilo, y 0-3 dobles enlaces, en donde el anillo carbocíclico y heterocíclico son sustituidos con 0-2 Rb; alternativamente, dos grupos R16 sobre átomos adyacentes se combinan para formar un anillo carbocíclico o heterocíclico de 3 a 7 miembros que comprenden, átomos de carbono y 0-2 heteroátomos seleccionados de N, NR11, O, y S(O)p, 0-1 carbonilo y 0-3 dobles enlaces, en donde el anillo carbocíclico o heterocíclico son sustituidos con 0-2 Rb; R18 es hidrogeno, alquilo C1-6 sustituido con 0-2 Ra; alquenilo C2-6 sustituido con 0-2 Ra, alquinilo C2-6 sustituido con 0-2 Ra, -C(O)Rc, C(O)ORc, -C(O)NR12R13, S(O)2Rh, -S(O)2NR12R13, (CH2)r-(carbociclo C3-10) sustituidos con 0-3 Rb, (CH2)r-(heterociclo de 5 a 10 miembros), que comprende: átomos de carbono y heteroátomos de 1-4 seleccionados de N, O, S(O)p, y sustituido con 0-3 Rb, Ra es independientemente, en cada apari
ARP060102745A 2005-06-27 2006-06-26 Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas. AR056867A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69459605P 2005-06-27 2005-06-27
US79706406P 2006-05-02 2006-05-02

Publications (1)

Publication Number Publication Date
AR056867A1 true AR056867A1 (es) 2007-10-31

Family

ID=37087734

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102745A AR056867A1 (es) 2005-06-27 2006-06-26 Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.

Country Status (13)

Country Link
US (2) US7728008B2 (es)
EP (1) EP1896466B1 (es)
JP (1) JP2008543972A (es)
KR (1) KR20080027890A (es)
AR (1) AR056867A1 (es)
AT (1) ATE505468T1 (es)
AU (1) AU2006261828A1 (es)
DE (1) DE602006021306D1 (es)
MX (1) MX2007016501A (es)
NO (1) NO20076424L (es)
PE (1) PE20070016A1 (es)
TW (1) TW200726764A (es)
WO (1) WO2007002637A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008527043A (ja) * 2005-01-19 2008-07-24 ブリストル−マイヤーズ スクイブ カンパニー 血栓塞栓障害治療用のｐ２ｙ１受容体阻害剤としての２−フェノキシ−ｎ−（１，３，４−チアジアゾール−２−イル）ピリジン−３−アミン誘導体および関連化合物
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) * 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002635A2 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
HK1199725A1 (en) 2011-08-29 2015-07-17 无限药品股份有限公司 Heterocyclic compounds and uses thereof
US9540323B2 (en) 2012-08-01 2017-01-10 Bristol-Myers Squibb Company 7-hydroxy-indolinyl antagonists of P2Y1 receptor
EP2880034B1 (en) 2012-08-01 2016-06-22 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor
EP2892898B1 (en) * 2012-08-01 2016-05-25 Bristol-Myers Squibb Company 7-hydroxy-spiropipiperidine indolinyl antagonists of p2y1 receptor
HK1209742A1 (en) 2012-11-20 2016-04-08 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
FI3853234T3 (fi) 2018-09-18 2025-07-28 Nikang Therapeutics Inc Fuusioituja trisyklisiä rengasjohdannaisia SRC-homologia-2-fosfataasin estäjinä
CN110305141B (zh) * 2019-07-18 2022-01-11 深圳市三启药物开发有限公司 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3118888A (en) * 1964-01-21 Acylated s-triazines and process for their preparation
NL280954A (es) * 1961-07-14
US4179563A (en) * 1978-05-19 1979-12-18 Warner-Lambert Company 3-Aryloxy-substituted-aminopyridines and methods for their production
US4186199A (en) 1978-11-02 1980-01-29 American Hoechst Corporation Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
JPS56166180A (en) * 1980-05-28 1981-12-21 Chugai Pharmaceut Co Ltd Dibenzoxazepine derivative and its preparation
JPS56167649A (en) 1980-05-30 1981-12-23 Chugai Pharmaceut Co Ltd Diphenyl ether derivative
US4663453A (en) 1983-05-18 1987-05-05 Hoechst-Roussel Pharmaceuticals Inc. Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
JPS62280847A (ja) 1986-05-30 1987-12-05 Konica Corp 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料
US4840947A (en) 1986-10-14 1989-06-20 Hoechst-Roussel Pharmaceuticals, Inc. Antiinflammatory and analgesic piperidin-4-yl-tetracyclic benzodiazepines and use thereas
JP2577222B2 (ja) * 1987-04-10 1997-01-29 興和株式会社 新規な置換アニリド誘導体
JPH0339740A (ja) 1989-07-06 1991-02-20 Konica Corp 転写型熱現像カラー感光材料
JP2951434B2 (ja) 1991-04-18 1999-09-20 三菱製紙株式会社 電子写真感光体
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
JP3395285B2 (ja) 1993-10-06 2003-04-07 日本製紙株式会社 感熱記録体
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE4443641A1 (de) 1994-12-08 1996-06-13 Bayer Ag Substituierte Carbonsäureamide
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
KR19980703048A (ko) * 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
US6143764A (en) * 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
PL329212A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Tetrahydro-beta-carbolynic compounds
CA2241687A1 (en) * 1996-10-30 1998-05-07 Kenneth A. Jacobson P2y receptor antagonists
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5858289A (en) 1997-02-24 1999-01-12 Global Consulting, Inc. Process for preparing compressed shape of ceramic fiber
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
NZ503491A (en) * 1997-11-10 2002-08-28 Bristol Myers Squibb Co 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
PT1042305E (pt) 1997-12-22 2005-10-31 Bayer Pharmaceuticals Corp Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
EE200100006A (et) 1998-07-06 2002-06-17 Bristol-Myers Squibb Company Bifenüülsulfoonamiidid kui duaalse angiotensiin-endoteliini retseptori antagonistid
SK4222001A3 (en) 1998-10-06 2001-10-08 Dainippon Pharmaceutical Co 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation
ATE290524T1 (de) 1998-10-20 2005-03-15 Takeda Pharmaceutical Aromatische aminderivate, verfahren zu ihrer herstellung und mittel, die diese enthalten
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
RU2242474C2 (ru) * 1999-03-12 2004-12-20 Бёрингер Ингельхайм Фармасьютиклз, Инк. Соединения, пригодные в качестве противовоспалительных агентов
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
HUP0202708A3 (en) * 1999-04-15 2004-12-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
AU5413600A (en) 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
CO5200760A1 (es) 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
WO2001023358A1 (en) 1999-09-27 2001-04-05 Sagami Chemical Research Center Pyrazole derivatives, intermediates for the preparation thereof, processes for the preparation of both and herbicides containing the derivatives as the active ingredient
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
WO2001051490A1 (en) 2000-01-14 2001-07-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
WO2001055146A1 (en) 2000-01-29 2001-08-02 Lg Chem Investment Ltd. FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
AU2000240570A1 (en) 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6693196B2 (en) * 2001-01-31 2004-02-17 The Procter & Gamble Company Couplers for use in oxidative hair dyeing
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
AU2002305260A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
BR0209485A (pt) 2001-05-08 2004-07-06 Schering Ag Antranilamidapiridinamidas seletivas como inibidores vegfr-2 e vegfr-3
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2002325381A1 (en) * 2001-07-31 2003-02-24 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
MXPA04000920A (es) 2001-08-06 2004-04-02 Pharmacia Italia Spa Derivados de aminoisoxazol activos como inhibidores de la cinasa.
CN101357914A (zh) 2001-09-21 2009-02-04 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
JP2005518365A (ja) * 2001-11-27 2005-06-23 メルク　エンド　カムパニー　インコーポレーテッド ４−アミノキノリン化合物
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
JP2005513154A (ja) 2001-12-26 2005-05-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 尿素誘導体
AU2003210969A1 (en) * 2002-02-11 2003-09-04 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
EP1478358B1 (en) * 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
US20030216396A1 (en) * 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
DE10213228A1 (de) 2002-03-25 2003-10-16 Bayer Ag Cyclopenten-Derivate
RU2004135386A (ru) * 2002-05-06 2005-07-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Тиадиазолы или оксадиазолы и их применение в качестве ингибиторов протеинкиназы jak
WO2004002481A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US20060058395A1 (en) 2002-08-01 2006-03-16 Neurosearch A/S Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
CA2495284A1 (en) 2002-09-05 2004-03-18 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
MXPA05005409A (es) 2002-11-21 2005-08-03 Neurosearch As Derivados de arilureido y su uso medico.
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
TWM252710U (en) * 2003-07-18 2004-12-11 Huei-Chiun Shiu Annealing equipment
EP1661879A4 (en) 2003-08-04 2006-11-29 Ono Pharmaceutical Co A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF
WO2005019240A2 (en) * 2003-08-13 2005-03-03 Amgen, Inc. Melanin concentrating hormone receptor antagonists
KR101122708B1 (ko) 2003-12-26 2012-03-26 마사토시 하기와라 Ｓｒ 단백질 인산화 제어 방법, 및 유효성분으로서 ｓｒ 단백질 활성 제어제를 함유하는 항바이러스제
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008500284A (ja) 2004-05-12 2008-01-10 ブリストル−マイヤーズ　スクイブ　カンパニー 血栓症の治療に有用なｐ２ｙ１レセプターのウレアアンタゴニスト
JP2008527043A (ja) 2005-01-19 2008-07-24 ブリストル−マイヤーズ スクイブ カンパニー 血栓塞栓障害治療用のｐ２ｙ１受容体阻害剤としての２−フェノキシ−ｎ−（１，３，４−チアジアゾール−２−イル）ピリジン−３−アミン誘導体および関連化合物
NZ588960A (en) * 2005-02-25 2012-06-29 Serenex Inc Tetrahydroindolone and tetrahydroindazolone derivatives
WO2007002584A1 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) * 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002635A2 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

Also Published As

Publication number Publication date
US7728008B2 (en) 2010-06-01
NO20076424L (no) 2008-03-18
EP1896466B1 (en) 2011-04-13
DE602006021306D1 (es) 2011-05-26
WO2007002637A1 (en) 2007-01-04
ATE505468T1 (de) 2011-04-15
US20100197716A1 (en) 2010-08-05
US8329718B2 (en) 2012-12-11
MX2007016501A (es) 2008-03-06
PE20070016A1 (es) 2007-02-11
WO2007002637B1 (en) 2007-03-01
EP1896466A1 (en) 2008-03-12
KR20080027890A (ko) 2008-03-28
JP2008543972A (ja) 2008-12-04
US20060293281A1 (en) 2006-12-28
AU2006261828A1 (en) 2007-01-04
TW200726764A (en) 2007-07-16

Similar Documents

Publication Publication Date Title
AR056867A1 (es) Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
AR053011A1 (es) Compuestos de heteroarilo como inhibidores del receptor p2y1, composiciones farmaceuticas que los contienen y su uso en la manufactura de un medicamento para el tratamiento de un trastorno tromboembolico
AR047449A1 (es) Amino-benzazoles como inhibidores del receptor p2y1, composiciones farmaceuticas y metodos de tratamiento
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
JP2013533317A5 (es)
AR067329A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
AR030301A1 (es) Compuestos ligandos para receptores de melanocortina, su uso en la preparacion de medicamentos y composiciones farmaceuticas
AR061114A1 (es) Arilimidazolonas y ariltriazolonas sustituidas asi como su uso
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
AR082633A1 (es) Analogos de tetraciclina
RU2487124C2 (ru) Новое амидное производное и его использование в качестве лекарственного средства
AR089910A1 (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de accion sistemica, metodos y usos de las mismas
PE20090042A1 (es) Analogos de ciclopamina
AR083842A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
JP2019504050A5 (es)
CL2004000918A1 (es) Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria
AR042956A1 (es) Inhibidores de girasa y usos de los mismos
AR047098A1 (es) Derivados de arilanilina como agonistas del receptor adrenergico beta2
AR082391A1 (es) Inhibidores biciclicos de acetil-coa y usos de los mismos
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
EP1933759A4 (en) METHOD FOR THE ADMINISTRATION OF RAPAMYCIN ANALOGUES WITH INFLAMMATORY INHIBITORS USING MEDICAL DEVICES
ECSP077417A (es) Nuevos derivados de aminopiridina que tienen acción inhibitoria selectiva de la aurora a
AR086676A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure